Bio-Techne FY2026: flat $1.22 billion revenue, GAAP EPS up to $1.16
Bio-Techne's fiscal 2026 was a flat year dressed up by prior-year charges: revenue was unchanged at $1.22 billion, GAAP EPS jumped to $1.16, and adjusted EPS inched to $1.93. With the company set to be acquired by Merck KGaA for $73 a share in cash, quarterly operating swings matter far less than deal completion. Read the numbers below as a closing snapshot, not a growth story.
1 · Expected vs. Actual
Free preview belowDiluted GAAP EPS was $0.35 in the quarter versus $(0.11) a year ago, and $1.16 for the year versus $0.46. Most of that swing comes from last year's non-recurring items: an $84.2 million impairment of assets held for sale and $41.8 million of certain litigation charges. Adjusted EPS, which excludes those, was $0.52 in the quarter (down from $0.53) and $1.93 for the year (up from $1.92), with the quarterly figure coming in just under the $0.5295 consensus.
Fourth-quarter revenue rose 1.0% to $321.2 million, but organic growth was 3.0% once a prior-year business held for sale is excluded. For the full year, reported and organic revenue were flat at $1.22 billion, so nothing is compounding at the top line. The Diagnostics and Spatial Biology segment carried the quarter with 8% organic growth, while Protein Sciences managed only 1%.
Log in to read 5 analyses a week for free
Create a free account to read 5 full earnings analyses each week — all five steps: expected vs. actual, guidance tracker, money flow, balance sheet and risks. Members get unlimited access.
Figures on this page come from the company's original SEC filings. The analysis is generated automatically and checked against validation rules, but may still contain errors or omissions. Not investment advice. · Generated 2026-09-17
Answers are based on the earnings release and the analysis above. Free accounts get 3 questions a week; members get 30 a day.